Telaprevir: New possibilities for antiviral treatment in patients with chronic hepatitis C

Abstract

The review considers the chemical structure, pharmacodynamics and pharmacokinetics of telaprevir, a new direct-acting antiviral agent, used to treat patients with chronic hepatitis C (CHC). The given data on Phase II and III clinical trials enable the authors to state the high efficacy of the drug in patients infected with hepatitis C virus type 1. The paper also provides data on the resistance of telaprevir and its drug interaction and denotes the place of the drug in the current antiviral treatment of patients with CHC.

Keywords

• chronic hepatitis c
• pegylated interferon-α
• ribavirin
• telaprevir